首页> 外文期刊>International journal of clinical pharmacology and therapeutics >Effect of HMG CoA reductase inhibitors on low-density lipoprotein cholesterol and C-reactive protein: systematic review and meta-analysis.
【24h】

Effect of HMG CoA reductase inhibitors on low-density lipoprotein cholesterol and C-reactive protein: systematic review and meta-analysis.

机译:HMG CoA还原酶抑制剂对低密度脂蛋白胆固醇和C反应蛋白的影响:系统评价和荟萃分析。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: HMG CoA reductase inhibitors (statins) have been claimed to decrease C-reactive protein (CRP), independent of their effect on low-density lipoprotein cholesterol (LDL-C). We conducted a systematic review and meta-analysis to investigate whether a relationship between the average effect of statins on LDL-C and CRP exists. DATA SOURCES: The literature search of the Medline and Cochrane databases between 1980 and August 2007 yielded 65 statin intervention studies with 94 treatment arms involving 16,260 patients reporting changes in both LDL-C and CRP. DATA EXTRACTION AND STATISTICAL METHOD: From each study relative changes in LDL-C and CRP were extracted. Random effects meta-analysis was used to obtain pooled summary estimates of the average study specific LDL-C and CRP reductions, in total and stratified by dose and type of statin. Weighted correlation analysis and metaregression analysis was used to investigate the relationship between the LDL-C and CRP changes adjusted for baseline values, type of statin and dose. RESULTS: Pooled summary estimates of statin-induced changes in LDL-C and CRP levels were -34.7% (95% CI: -37.7% to -31.8%) and -30.8% (95% CI: -39.4% to -22.3%), respectively. We found a positive correlation between the average LDL-C and CRP reduction (r = 0.49, p = 0.010) which increased when adjusting for pre-treatment concentrations (r = 0.79, p < 0.001). The effect of statins on CRP were strongly related to the changes in LDL-C and baseline concentrations, independent of the type and dose of statin used. CONCLUSION: Our meta-analysis shows a strong correlation between statin-induced reductions in LDL-C and CRP, which has not been evident from individual studies. Measuring CRP in addition to LDL-C in the monitoring of statin treatment is currently not warranted.
机译:目的:HMG CoA还原酶抑制剂(他汀类药物)据称能降低C反应蛋白(CRP),而与它们对低密度脂蛋白胆固醇(LDL-C)的作用无关。我们进行了系统的审查和荟萃分析,以研究他汀类药物对LDL-C和CRP的平均作用之间是否存在关系。数据来源:1980年至2007年8月间对Medline和Cochrane数据库进行的文献检索产生了65种他汀类药物干预研究,其中94种治疗方案涉及16260名报告LDL-C和CRP改变的患者。数据提取和统计方法:从每项研究中,提取了LDL-C和CRP的相对变化。随机效应荟萃分析用于汇总平均研究特定LDL-C和CRP减少量的汇总摘要估计值,并按他汀类药物的剂量和类型进行分层。加权相关分析和Meta回归分析用于研究经基线值,他汀类药物和剂量调整后的LDL-C和CRP变化之间的关系。结果:他汀类药物诱导的LDL-C和CRP水平变化的汇总摘要估计为-34.7%(95%CI:-37.7%至-31.8%)和-30.8%(95%CI:-39.4%至-22.3%) ), 分别。我们发现,平均LDL-C与CRP降低之间存在正相关关系(r = 0.49,p = 0.010),当调整治疗前浓度(r = 0.79,p <0.001)时,正相关性增加。他汀类药物对CRP的影响与LDL-C和基线浓度的变化密切相关,而与所用他汀类药物的类型和剂量无关。结论:我们的荟萃分析显示,他汀类药物引起的LDL-C减少与CRP减少之间存在很强的相关性,这在个别研究中尚无定论。目前不保证在监测他汀类药物治疗中除LDL-C外还测量CRP。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号